Idioma:

Molecular classification of prostate cancer using curated expression signatures

Markert, Elke K. ; Mizuno, Hideaki ; Vazquez, Alexei ; Levine, Arnold J.

Proceedings of the National Academy of Sciences - PNAS, 2011-12, Vol.108 (52), p.21276-21281 [Periódico revisado por pares]

United States: National Academy of Sciences

Texto completo disponível

Citações Citado por

Enviar para

Título:
Molecular classification of prostate cancer using curated expression signatures
Autor: Markert, Elke K. ; Mizuno, Hideaki ; Vazquez, Alexei ; Levine, Arnold J.
Assuntos: Bayes Theorem ; Biological Sciences ; Cancer ; Cytokines ; Datasets ; Embryonic Stem Cells - metabolism ; Gene expression ; Gene Expression Profiling ; Genetic mutation ; Health outcomes ; Humans ; Induced pluripotent stem cells ; Male ; Medical prognosis ; Metastasis ; Microarray Analysis ; Neoplasm grading ; Neoplasm Grading - methods ; Oncogene Proteins, Fusion - metabolism ; Oncology ; Prognosis ; Prostate cancer ; Prostatic Neoplasms - classification ; Prostatic Neoplasms - genetics ; PTEN Phosphohydrolase - genetics ; RNA, Messenger ; Signatures ; Stem cells ; Sweden ; Tumor Suppressor Protein p53 - genetics ; Tumors ; Watchful Waiting
É parte de: Proceedings of the National Academy of Sciences - PNAS, 2011-12, Vol.108 (52), p.21276-21281
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Contributed by Arnold J. Levine, October 21, 2011 (sent for review September 6, 2011)
Author contributions: E.K.M. and A.J.L. designed research; E.K.M., H.M., and A.V. performed research; E.K.M. analyzed data; and E.K.M., A.J.L. wrote the paper.
Descrição: High Gleason score is currently the best prognostic indicator for poor prognosis in prostate cancer. However, a significant number of patients with low Gleason scores develop aggressive disease as well. In an effort to understand molecular signatures associated with poor outcome in prostate cancer, we analyzed a microarray dataset characterizing 281 prostate cancers from a Swedish watchful-waiting cohort. Patients were classified on the basis of their mRNA microarray signature profiles indicating embryonic stem cell expression patterns (stemness), inactivation of the tumor suppressors p53 and PTEN, activation of several oncogenic pathways, and the TMPRSS2—ERG fusion. Unsupervised clustering identified a subset of tumors manifesting stem-like signatures together with p53 and PTEN inactivation, which had very poor survival outcome, a second group with intermediate survival outcome, characterized by the TMPRSS2—ERG fusion, and three groups with benign outcome. The stratification was validated on a second independent dataset of 150 tumor and metastatic samples from a clinical cohort at Memorial Sloan—Kettering Cancer Center. This classification is independent of Gleason score and therefore provides useful unique molecular profiles for prostate cancer prognosis, helping to predict poor outcome in patients with low or average Gleason scores.
Editor: United States: National Academy of Sciences
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 7 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Molecular classification of prostate cancer using curated expression signatures

Markert, Elke K. ; Mizuno, Hideaki ; Vazquez, Alexei ; Levine, Arnold J.

United States: National Academy of Sciences

Buscando em bases de dados remotas. Favor aguardar.